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Abstract
Background: Leukocyte adhesion deficiency 1 (LAD1) is an inherited disorder of neutrophil function. Nonsense mutations in
the affected CD18 (ITB2) gene have rarely been described. In other genes containing such mutations, treatments with
aminoglycoside types of antibiotics (e.g., gentamicin) were reported to partially correct the premature protein termination,
by induction of readthrough mechanism.
Methodology/Principal Findings: Genetic analysis was performed on 2 LAD1 patients. Expression, functional and
immunofluorescence assays of CD18 in the patients were used to determine the in-vivo and in-vitro effects of gentamicin-
induced readthrough. A theoretical modeling of the corrected CD18 protein was developed to predict the protein function.
Results: We found a novel premature termination codon, C562T (R188X), in exon 6 of the CD18 gene that caused a severe
LAD1 phenotype in two unrelated Palestinian children. In-vivo studies on these patients’ cells after gentamicin treatment
showed abnormal adhesion and chemotactic functions, while in-vitro studies showed mislocalization of the corrected
protein to the cytoplasm and not to the cell surface. A theoretical modeling of the corrected CD18 protein suggested that
the replacement of the wild type arginine by gentamicin induced tryptophan at the position of the nonsense mutation,
although enabled the expression of the entire CD18 protein, this was not sufficient to stabilize the CD18/11 heterodimer at
the cell surface.
Conclusion: A novel nonsense mutation in the CD18 gene causing a complete absence of CD18 protein and severe LAD1
clinical phenotype is reported. Both in vivo and in vitro treatments with gentamicin resulted in the expression of a corrected
full-length dysfunctional or mislocalized CD18 protein. However, while the use of gentamicin increased the expression of
CD18, it did not improve leukocyte adhesion and chemotaxis. Moreover, the integrity of the CD18/CD11 complex at the cell
surface was impaired, due to abnormal CD18 protein and possibly lack of CD11a expression.
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Introduction
Leukocyte adhesion deficiency 1 (LAD1) is an inherited disorder
of neutrophil function characterized by recurrent bacterial
infections and impaired pus formation and wound healing [1].
The pathophysiology of LAD1 includes abnormalities of a wide
variety of adhesion-dependent functions of hematopoietic cells due
to deficiency of the beta-2 integrin (CD18, ITGB2) subunit [2].
Different types of mutations have been described in the CD18
gene [3]. These mutations interfere with the CD18/CD11
interaction and cause the lack of beta-2/alpha-L (CD18/
CD11a), beta-2/alpha-M (CD18/CD11b), and beta-2/alpha-X
(CD18/CD11c) expression. Nonsense mutations in the CD18
gene have rarely been described [4]. This type of mutation
characteristically results in truncated or completely missing protein
production and is associated with a severe disease phenotype. An
aminoglycoside family of antibiotics (e.g., gentamicin) was recently
reported to partially correct the effect of nonsense mutations by
specifically recognizing ribosomes and by promoting a read-
through mechanism for the modulation of translation and
miscoding [5]. The binding of aminoglycosides to ribosomes also
enhances the ability of releasing factors, such as RF1 and RF2, to
stabilize the nascent protein strand in the ribosome for further
elongation [6]. Furthermore, the expression of various gene
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regulated by treating cells with aminoglycoside antibiotics [7].
Consequently, aminoglycoside antibiotics have been found to
allow ribosomes to readthrough inappropriately inserted stop
codon mutations in both human [8] and animal [9] models. The
mechanism of translation termination is highly conserved among
most organisms and is almost always signaled by an amber (UAG),
ochre (UAA), or opal (UGA) termination codon [10]. By reducing
the accuracy of translation, aminoglycosides increase the frequen-
cy of erroneous insertions at the nonsense codon and permit
translation to continue to the end of the gene. Aminoglycoside
antibiotics usually insert glutamine at nonsense UAG or UAA or
tryptophan at nonsense UGA sites [11] albeit at extremely modest
efficiencies of the affected genes. Indeed, patients suffering from
different heritable diseases, such as cystic fibrosis, muscular
dystrophies, hemophilia, lysosomal storage disorder or ataxia
telangiectasia due to stop codon mutations experienced clinical
and laboratory improvement after gentamicin treatment [12],
[13], [14], [15], [16]. For example, expression of full-length CFTR
protein at the apical cell membrane was observed in cystic fibrosis
patients [17]. Moreover, suppression of stop mutations in the
CFTR gene by parenteral gentamicin could be predicted in-vitro
[18]. These clinical studies paved the way to the development of
orally bioavailable small molecule modality that is designed to
induce ribosomes to selectively read through some premature stop
codons during mRNA translation, [19], however, raised some
controversies regarding its application in other premature stop
codons.
We describe here a novel premature termination codon in the
CD18 gene causing severe LAD1 phenotype in two Palestinian
children. We investigated the in-vivo and in-vitro effects of
gentamicin-induced readthrough in the CD18 protein of these
patients. We also show the effect of gentamicin treatment on the
expression of CD11 molecules and their interaction with CD18 at
the cell surface.
Methods
Patients
Two patients with a clinical phenotype suggestive of LAD1 and
age-matched healthy control were studied. Parents provided
signed informed consent to obtain blood from their children, to
use tissues obtained from their children, to create cell lines and to
test these samples for the effects of gentamicin treatment on the
CD18 protein. Gentamicin was used purely for clinical purposes
which were not related to this study. The Institutional Review
Board (Sheba Medical Center, Tel Hashomer) approved human
involvement, use of patient tissue and cell line creation. De novo
lymphoclastiod cell lines were prepared. The consent and the
IRB approval received extend to a lymphoblastoid cell line
control that was previously approved by the institute IRB and
published [20].
Genetics
Genomic DNA was extracted from the studied patients’
peripheral blood mononuclear cells (PBMCs). The CD18 gene
was sequenced using the appropriate primers as previously
described [21]. In addition, RNA was extracted (PerfectPure
RNA Tissue kit,59 prime, Germany) and cDNA was prepared
(High capacity cDNA RT kit, Applied Biosystems,USA). The
mutation region within CD18 transcripts obtained from both
patients was PCR amplified and sequenced using the primers:
Forward 59- CCTCAACGAGATCACCGAGTC- 39 and Re-
verse: 59-GTTGCGCCAGCCGATTTCCTC- 39.
Cell lines
Epstein-Barr virus (EBV)-transformed lymphoblasts were pre-
pared from lymphocytes obtained from each patient. These cell
lines were maintained in RPMI 1640 supplemented with 10%
fetal calf serum (FCS), pen-strep (100 mcg/ml) and 2 mM
glutamine at 37uC in a humidified atmosphere of 5% CO2.
The cells were grown in the presence or absence of various con-
centrations of gentamicin sulphate 50 mg/ml (Biological Indus-
tries Inc., Beit HaEmek, Israel), and were harvested at specified
times.
Neutrophil function
Neutrophil function was determined while both patients were
receiving gentamicin treatment. The neutrophils were isolated
(99% purity) from heparinized blood by dextran sedimentation,
Histopaque gradient, and erythrocyte lysis, as described by
Boyum [22]. They were re-suspended for chemotaxis studies in
M199 medium (Biological Industries Inc., Beit HaEmek, Israel)
(10
6 cells/mL) and for adhesion in phosphate buffer saline (PBS)
with 0.1% albumin and 0.2% glucose (5610
6 cells/mL).
Chemotaxis was assessed in a 48-well chemotaxis chamber
through a 3-mcm pore size filter [23] and induced by 1 mcM
of the chemoattractant N-formyl-Met-Leu-Phe (fMLP) (Sigma-
Aldrich, St. Louis, MO). Random migration was conducted in the
presence of medium M199. Calculations of net chemotaxis were
made by subtracting the random from the chemotactic migration
(fMLP-stimulated neutrophils). All procedures were performed in
quadruplicates. Cell adhesion to the gelatin surface was assessed
as previously described [24]. Briefly, cells were labeled with 0.1%
Calcein (MW 994.87; Molecular Probes-Eugene, Oregon) and
incubated for 30 min at 37uC with either of the stimulates PMA
(100 ng/ml) or fMLP (0.1 mcM) in a 24-well plate. HTAB lysis
solution (0.1% Tween 20 [Sigma], 0.1% HTAB [Sigma], 0.2%
BSA, 20 mM EDTA) was added. Fluorescence of the lysates was
measured by a spectrofluorophotometer (Shimadzu, Tokyo,
Japan) at an excitation wavelength of 485 nm and an emission
of 535 nm.
Flow cytometry analysis
Whole blood or transformed lymphoblasts from the patients and
controls were collected and incubated with anti-CD18, anti-
CD11a, anti-CD11b and anti-CD11c antibodies (Coulter Diag-
nostics). Red blood cells (RBCs) were lysed and white blood cells
(WBCs) were washed with PBS. Lymphocytes, granulocytes and
monocytes were gated. The cell surface expression of the various
markers on these cells and the lymphoblasts was measured using
flow cytometry (Epics V; Coulter Electronics, Hialeah, FL or
Becton Dickinson CANTO II, BD Biosciences, NJ, USA, Diva
software).
Protein extraction and Western immunoblotting
EBV-transformed cells were treated with gentamicin (600, 1000
or 2000 mcg/ml) for 3 or 5 days. They were harvested and lysed
with a lysis buffer containing 150 mM NaCl, 50 mM Hepes
pH 7.4, 1 mM EDTA, 1 mM EGTA 1.5 mM MgCl 2, 1% triton-
X, and 10% glycerol in the presence of a protease inhibitor
cocktail (complete; Roche, Mannheim-Germany). Proteins were
separated on 10% SDS-PAGE, transferred to a nitrocellulose
membrane (Schleicher & Schuell, Germany) and probed with anti-
CD18 antibody (abcam). ECL
TM (Pharmacia Biotech, NJ, USA)
chemiluminescent reagents were used for signal detection.
Intensity of the band was analyzed using the Image EZ-Quant
software package (EZ-Quante LTD., Israel).
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EBV-transformed cells were treated with gentamicin
(1000 mcg/ml) for 5 days, harvested and cytospan onto slides.
They were then fixed with ice-cold methanol and ice-cold acetone,
washed with Tris-buffered saline (TBS; 100 mM Tris-HCl
pH 7.5, 150 mM NaCl) and blocked using 5% skim milk in
TBS containing 0.1% Tween 20 (TBS-T). Mouse monoclonal
anti-integrin B2 (CD18) antibody (Santa Cruz Biotechnology Inc.,
USA) was used to detect CD18 protein. The slides were mounted
using immunofluore containing 49,6-diamidino-2-phenylindolem
(DAPI) for nuclear staining, and analyzed by optic grid fluorescent
microscopy (Olympus).
Structural bioinformatics
A 3D model of CD18 protein was built by homology modeling
using Modeller [25]. A Ca-match server [26] was used to
structurally align the model with ITB3 (CD61). Images were
obtained using Chimera [27].
Results
Clinical findings
The two studied patients were both males of Palestinian descent.
Patient #1 was 3 months old and Patient #2 was 12 months old at
presentation. They belonged to two unrelated families and both
were born to healthy consanguineous parents. Infantile fatalities at
early age due to recurrent infections were known to have occurred
in both families. The two patients had the typical clinical features
of LAD1, including delayed umbilical cord separation, extremely
high leukocyte counts, recurrent infections and abnormal wound
healing. Their clinical details are summarized in Table 1. Patient 1
had inconsistent changes in leukocyte counts during and after
treatment with gentamicin. Patient 2 displayed a consistent
reduction in leukocyte counts during the treatment with
gentamicin (from 41.3 to 21.9 cells per mm
3). Yet both patients
displayed a severe disease phenotype that resulted in the death of
Patient #1a t5 months of age due to severe pseudomonas
infection before he could undergo bone marrow transplantation
(BMT). Patient #2 underwent a BMT at age 15 months and
currently is alive and well.
Genetics
Sequence analysis of the patients’ CD18 coding exons revealed
a novel homozygous C562T nonsense mutation in exon 6 of the
gene (Figure 1A). This mutation predicts a putative arginine to
stop codon substitution (R188X) at the protein level (a codon
change from CGA to TGA). This novel premature stop codon
mutation resides within the highly conserved b-I domain of the
various B-integrins including the ITB2/CD18 protein (Figure 1C).
Therefore, we anticipated that such a mutation would yield either
a 188 amino acid long truncated form of CD18 or the complete
absence of this protein. Autosomal recessive inheritance of this
mutation was confirmed by the heterozygosity of the mutated
nucleotide in the asymptomatic parents and siblings of both
families (Figure 1A).
In-vivo induction of CD18 gene expression by gentamicin
Patient 1. Upon admission, patient #1 was on gentamicin
treatment for two weeks because of a skin infection. During this
treatment, his CD11/CD18 workup showed detectable expression
of the CD18 protein on total lymphocytes (75% of the cells),
monocytes (93%) and granulocytes (96%), compared to a healthy
control (94–99% of cells) (Figure 2 and Table 2). CD11b and
CD11c were also detected while CD11a was undetected (Table 2).
One week later, gentamicin was stopped due to renal toxicity and
acute renal failure. A repeated immune workup that was
performed one week after stopping gentamicin treatment
revealed significant reduction in the expression of the CD18
protein on total lymphocytes (54%), monocytes (35%) and
granulocytes (78%) (Figure 2 and Table 2). In addition, reduced
expression of CD11b and CD11c on different cell types was
detected, while CD11a remained undetectable (Table 2).
Patient 2. On presentation, patient #2 had undetectable
expression of CD18/11 heterodimers on lymphocytes, expression
of CD11c (32% of cells) on monocytes and expression of CD11c
(9%) on granulocytes. CD11a was not detected on any of the
examined cells (Table 2). The immune workup was repeated after
two weeks of gentamicin treatment that was empirically prescribed
for an acute febrile episode. Surprisingly, the expression of CD18
was significantly increased on the granulocytes (66%). In addition,
the expression of CD11b and CD11c on different cell types had
increased while CD11a remained undetectable (Figure 2 and
Table 2). In order to verify that the elevation in CD18 expression
was not due to a reversion in the mutated CD18 transcript but
rather due to post-translation change in the protein, RNA was
extracted from lymphocytes of both patients during gentamicin
treatment, cDNAs were prepared and CD18 transcripts were
sequenced. In both samples the C562T (R188X) germline
mutation was found, suggesting post-translation gentamicin-
induced correction as expected (Figure 1B).
Table 1. Patient characteristics.
Patient #1 Patient #2
Sex Male Male
Age at presentation, m 3 12
Age at umbilical cord separation 2.5 3
Family fatalities at early age Positive Positive
Type of infection Deep and superficial abscesses, necrotic
lesion (cervical)
Deep and superficial abscesses, necrotic lesions
(wrist, thigh)
Wound healing Abnormal Abnormal
White blood count/neutrophils, mm
3 54.8/34.6 41.3/24
Outcome Death due to sepsis Alive post bone marrow transplantation
doi:10.1371/journal.pone.0013659.t001
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gentamicin
EBV-transformed lymphoblasts from both patients were treated
for 3–5 days with incremental doses of gentamicin (600–
2000 mcg/ml). The cell surface expression of the CD11/18
heterodimers was determined by FACS analysis. The expression of
CD18 and CD11 proteins in both cell lines was undetectable or
very low before gentamicin treatment and increased slightly with
gentamicin treatment (Table 3). There was a similar trend for
CD18/11 expression at both 3 and 5 days of gentamicin
treatment. The CD18 level had increased to a maximal expression
of 2% after 3 days of treatment with 600 mcg/ml gentamicin.
Figure 1. R188X nonsense mutation in ITGb2/CD18. a. DNA sequences of the mutation region in exon 6 of CD18 gene in the two patients,
their parents, one sister of patient #2 and one brother of patient #2. b. cDNA sequences of the mutation region in CD18 transcripts in the two
patients c. Schematic structure of ITGb2/CD18 protein, its domains and the position of the premature stop mutation. PSI indicates the plexin-
semaphorin-integrin domain; HD, hybrid domain; EGFD, EGF-like domain; bTD, b-tail domain; PM, plasma membrane.
doi:10.1371/journal.pone.0013659.g001
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patients’ cells, a slight expression of CD11a was detected after
gentamicin treatment (Table 3). The protein expression level of
CD18 was detected by western blot (Figure 3): expression of the
CD18 protein (95 KD band) had increased after 3 days following
gentamicin treatment. This effect was dose-dependent, reaching a
maximal effect after 3 days of 2000 mcg/ml gentamicin treatment.
These results showed that the slight elevation of CD18 expression
as detected by FACS analysis upon gentamicin treatment did not
correlate with the elevation of the protein level as detected by
western blot. This finding suggested that although gentamicin
induced high expression of CD18 protein, only part of the protein
was expressed on the cell surface as detected by FACS.
Immunolocalization studies of the CD18 protein during treatment
with gentamicin were performed to check this possibility.
Immunolocalization of CD18
To test our hypothesis that gentamicin-induced readthrough
caused intact protein formation but not the appropriate localiza-
tion on the cell surface, lymphoblast cells derived from the two
patients were treated with gentamicin and harvested for
immunofluorescence staining. Their CD18 immuno-localization
was compared to that of untreated lymphoblasts derived from
healthy control (Figure 4). After undergoing gentamicin treatment,
cells from both patients showed cytoplasmic staining but not cell
membrane staining of the CD18 protein. In contrast, cells from
healthy control showed clear staining of CD18 at the cell
membrane (Figure 4).
Chemotaxis and cell adhesion
Upon neutrophil stimulation with fMLP and PMA, the
adhesion index in both patients was unchanged and remained 1.
In contrast, two healthy controls exhibited significantly increased
adhesion index (values of 3.3–7.2 and 9.6–9.8 following fMLP and
PMA stimulations, respectively). An increased adhesion index was
observed also in the patients’ mothers upon neutrophil stimulation
(2.3–3.3 and 4.9–5.1 for fMLP and PMA stimulation, respectively.
Both mothers were heterozygote carriers of the CD18 nonsense
mutation). Thus, the net chemotaxis (fMLP-stimulated minus
unstimulated cells) of both patients was significantly reduced (4
and 19 cells/field) compared to the healthy controls (42–57 cells/
field) and to their mothers (41 and 75 cells/field). These findings
indicate a significant neutrophil dysfunction.
Theoretical modeling of the CD18 protein
In order to better understand why the corrected gentamicin-
induced readthrough CD18 was mislocalized, we computerized a
homologous model of CD18 containing the wild-type arginine
residue or the replaced putative tryptophan residue (Figure 5).
Upon gentamicin treatment, it is assumed that this residue was
inserted during translation instead of the stop codon at amino acid
position 188. The model suggests that tryptophan is located in a
relatively exposed and flexible loop in CD18 which is not
conserved between the integrin B-subunits. Superimposing the
model on top of an experimentally available B-subunit in complex
(avb3 complex) allowed us to predict that this residue is in close
proximity to the a-b interface, assuming that the interface is
similar to that which is between CD18 and its a-subunit partners.
Discussion
Nonsense mutations have rarely been described in the CD18
gene [4]. This type of mutation was reported to correlate with a
severe clinical phenotype in other primary immunodeficiencies,
such as Wiskott-Aldrich syndrome, [28], as well as in non-
immunodeficiency inherited diseases [29]. Herein, we describe a
novel R188X nonsense mutation in the CD18 gene in two
children of Palestinian descent with a possible common founder
probound. A normal heterozygote carrier for this mutation has
been reported [30]. Both patients described by us, had significantly
impaired wound healing in addition to the other typical LAD1
Table 2. Expression of CD11/18 in patients 1 and 2 treated with or without gentamicin.
Cell CD18 CD11a CD11b CD11c
GentamicinTreatment - + - + - + - +
Patient #1 Lymph 54 (19) 75 (8) 0 0 40 (12) 75 (16) 0 25
Mono 35 93 0 0 40 87 52 48
Gran 78 (40) 96 (31) 0 0 76 92 72 71
Patient #2 L y m p h 000002 2 00
Mono 000005 4 3 2 5 5
Gran 0 (7) 66 (16) 0 0 0 (5) 50 (7) 9 82
Control Lymph 96 76 71 8
Mono 94 94 95 96
Gran 99 85 99 60
Results are given in percents. When weak expression and/or low number of events were detected, MFI (mean fluorescence intensity) was measured as well, and results
are presented in brackets.
Lymph indicates lymphocytes; Mono, monocytes; Gran, granulocytes.
doi:10.1371/journal.pone.0013659.t002
Figure 2. CD18 and CD11b cell surface expression upon gentamicin treatment in vivo. Whole blood samples from patient #1 (a), patient
#2 (b) and healthy control (c) were incubated with anti-CD18 or anti-CD11b antibodies (Coulter Diagnostics). Lymphocytes (Lymph.) and
granulocytes (Granul.) were gated and the expression of CD18 or CD11b on their cell surface was measured using flow cytometry (Epics V; Coulter
Electronics, Hialeah, FL or Becton Dickinson CANTO II, BD Biosciences, NJ, USA, Diva software). Unstained cells obtained from patient #1 (a) were used
as the control to set the M1 threshold. The percent of cells expressing the relevant cell surface marker in each case is indicated.
doi:10.1371/journal.pone.0013659.g002
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tation resembles that of CD18 null mice [31]. The latter was
shown to suffer from spontaneous skin ulceration and chronic
dermatitis with extensive facial and submandibular erosions, in
addition to the typical LAD1 clinical findings. It can be concluded
that the severe and identical clinical phenotype in both humans
and mice is attributable to the complete absence of the CD18
protein. Therefore, restoring this protein and its function in LAD1
patients is of great importance.
To date, the only curative treatment in such severe cases of
LAD1 is allogeneic BMT [32], [33]. However, alternative
treatments are often required for patients who are waiting to
undergo a BMT or when the procedure is not available. One of
these alternatives may be the correction of the nonsense mutated
dysfunctional CD18 protein by the gentamicin-induced read-
through mechanism. The identification of a clinically feasible
method to suppress premature stop mutations within the CD18
gene might be of considerable benefit to patients with LAD1 as
well as to those with other diseases caused by stop mutations. We
sought to determine whether this mechanism is applicable to the
specific nonsense mutation carried in the CD18 gene of two
patients while they were awaiting BMT. Before treatment, the
reported mutation resulted in undetectable CD18 protein levels in
both patients’ cells, either because the putative truncated protein
was completely missing or it was misfolded. Our results suggest
that gentamicin treatment induced readthrough of the mutated
gene, yielding a corrected full-length CD18. The fact that
sequencing of both patients cDNA revealed the germline mutation
suggests a post-translation gentamicin-induced correction and not
a reversion of the mutated CD18 gene. This treatment did not,
however, improve the clinical manifestation of the condition or the
leukocyte adhesion and chemotaxis. Indeed, the gentamicin-
induced corrected full-length protein was either dysfunctional or
mislocalized.
The novel nonsense type of mutation that we found enabled us
to test the proof of principle that interventions designed to read
through premature stop mutations may at least partially reverse a
clinical phenotype. Our study is important in light of the
controversies regarding the effect of gentamicin-induced read-
through that exists even in the same diseases [34], [35]. In general,
targets with the UGA stop codon, such as that displayed in our
patients, showed a higher translational readthrough than those
with other stop codon changes [10]. We showed increased
production of the entire CD18 protein (western blot analysis) in
the lymphoblasts after treatment with gentamicin. Since stop
codons in various genes show a broad spectrum of readthrough
efficiency in response to gentamicin, the extent of increase in
CD18 expression that followed this treatment was surprisingly
high. For example, patients with muscular dystrophies [35] and
cystic fibrosis [18] were shown to have readthrough levels of the
affected gene ranging from only 0.05% to 2.65%. Despite the
significant elevation in the expression of the corrected CD18, only
a slight change in the cell surface expression of the heterodimer
CD11/18 was demonstrated in lymphoblasts after gentamicin
treatment (up to 2% CD18), as demonstrated both by FACS
analysis and immunofluorescent studies of these cells. This non-
Table 3. In-vitro induction of CD18.
Treatment CD18 CD11a CD11b CD11c
Patient #1 - 0 0 0.8 0.4
600 0.6 0 1.1 0.5
1000 1 0 0.3 0.2
2000 0.5 0 0.8 0.2
Patient #2- 0 0 3 3 2 3
600 2 1.7 34 11
1000 0 0.9 14 6
2000 0 1.6 8 6
Control - 81 88 22 30
doi:10.1371/journal.pone.0013659.t003
Figure 3. In vitro induction of CD18 protein expression by gentamicin treatment. The two patients’ Epstein-Barr virus-transformed cells
were treated with increasing concentrations of gentamicin for 3 days. Proteins were extracted from whole cell lysates for western blot analysis (upper
panels) using anti-CD18 antibodies (abcam) and anti-tubulin antibody (Sigma) for equal loading control. Intensities of the CD18 bands were
calculated using Image EZ-Quant software package (EZ-Quante LTD., Israel), normalized to the untreated samples (lower panels).
doi:10.1371/journal.pone.0013659.g003
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the relative difficulty to obtain significant changes in leukocyte
functions.
CD18 expression is required for the normal expression of the
CD11 components of the heterodimers [36], yet their expression
does not confirm function [37]. Differences in CD18/CD11
expression in LAD1 patients due to the different homeostasis of
their leukocytes have never been addressed before. By testing the
effect of gentamicin on the CD18 level, we could also determine
the effect of the corrected CD18 on the proper cell surface
expression of the different CD11 molecules and the integrity of the
entire CD18/11 complex. Interestingly, while CD11b and CD11c
were positively affected by the increased level of CD18, CD11a
remained undetectable by FACS analysis. Therefore, we can
speculate that a gentamicin-induced readthrough has an effect on
CD18 expression which allows its ability to associate with the
CD11b and CD11c subunits but not with the CD11a subunit at
the cell surface. We hypothesize that the inability of the corrected
CD18 to bind CD11a is due to the gentamicin induced
replacement of tryptophan residue instead of the wild type
arginine at amino acid position 188 of CD18 protein, as suggested
also by our computerized modeling analysis of the predicted
heterodimer. While the truncated CD18 protein that resulted from
the premature stop codon was either degraded or misfolded and
therefore dysfunctional, it is likely that the corrected CD18 was not
properly folded because the tryptophan replacement is not located
in the protein core. Since there is no available structure to depict
the CD18/CD11 complex, our proposed model and its orientation
with respect to the CD51/CD61 resolved complex suggests that
the tryptophan is located close to the interface and might interact
with or sterically disturb any interaction with its alpha chain
partners, such as CD11a. In any event, the charge difference (i.e.,
aromatic tryptophan replacing positively charged arginine) might
affect binding, even in longer range interactions.
Since we could not significantly affect the neutrophil function
despite elevating the expression of CD18, CD11b and CD11c, we
can also speculate that CD11a is a crucial factor for the CD18/11
adhesion-dependent functions of hematopoietic cells [38]. Indeed,
the involvement of CD18/CD11a heterodimer in the adhesion of
cytotoxic T cells to their target cells, including the delivery of a
distinct signal essential for directing released granules to antigen-
bearing target cells to mediate their destruction, is unique [39]. An
alternative explanation forthe dysfunctional cells is thatexpression of
theotherCD18/11componentswerenotenough,thusahigherlevel
of readthrough would be required in order to restore appropriate
localization of the CD18 protein and full functional activity. This
speculation can provide a rationale for the development of future
therapeuticmodalitiesaimingtomaximizethereadthroughpotential
or to improve the function of the corrected protein at the cellsurface.
For example, Nudelman et al. [40] recently described a novel NB54
aminoglycoside with reduced toxicity and enhanced suppression of
disease-causing premature stop mutations in cells that originated
fromvarioushereditarydiseaseswhichimprovesbothexpressionand
function of the corrected protein.
In summary, we presented a novel premature termination
codon mutation in the CD18 gene of two Palestinian children with
severe LAD1 phenotype. This mutation enabled us to test the
proof of concept designed to readthrough premature stop
mutations. We showed that a corrected full-length CD18 is
produced as a result of gentamicin treatment both in vivo and in
Figure 4. Immuno-localization of CD18 upon treatment with gentamicin. The two patients’ Epstein-Barr virus-transformed cells were treated
with gentamicin (1000 mg/ml) for 5 days. Cells were cytospun, fixed and immunostained with mouse monoclonal anti integrin b2 (CD18) antibody
(Santa Cruz Biotechnology Inc., USA). Slides were mounted using immunofluorescence and DAPI for nuclear staining and analyzed by optic grid
fluorescence microscopy (Olympus). a. 1000-fold magnification of healthy control’s Epstein-Barr virus-transformed lymphocytes b. 600-fold
magnification of gentamicin untreated (upper panel) and treated (lower panel) lymphoblastoids derived from patients 1 and 2. c. 1000-fold
magnification of gentamicin untreated (left panel) and treated (right panel) lymphoblastoids derived from patient 1. N indicates nucleus; PM, plasma
membrane; C, cytoplasm.
doi:10.1371/journal.pone.0013659.g004
Gentamicin for CD18 Deficiency
PLoS ONE | www.plosone.org 8 November 2010 | Volume 5 | Issue 11 | e13659vitro, although the protein is either dysfunctional or mislocalized.
In addition, we found that the integrity of the CD18/CD11
complex was impaired, possibly due to lack of CD11a expression.
Our results should encourage the search for more effective
aminoglycoside readthrough compounds to treat LAD1 and other
potential genetic disorders caused by nonsense mutations.
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